Achieve Life Sciences offers a compelling risk/reward profile with its promising smoking cessation therapy, cytisinicline.

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...